[ad_1]
The Utah Innovation Fund, a state-backed venture capital fund located at the Thomas S. Monson Center in downtown Salt Lake City, has announced three investments totaling $700,000, all of which is for start-up companies related to life sciences.
3Helix, Rebel Medicine, and Inherent Biosciences recently received funding totaling $700,000 from the Utah Innovation Fund. 3Helix and Rebel Medicine are part of the University of Utah’s startup portfolio. Inherent Biosciences is a collaboration with BYU and the U of U.
“The Utah Innovation Fund is deeply committed to advancing the advancement of pioneering technologies, and these companies are making great strides in the field of biomedical innovation,” said Gabi Telles, managing director of the Utah Innovation Fund. “
Jefferson Moss, Managing Director of the Innovation Fund, agreed, adding: solution. ”
3Helix aims to address problems arising from damage to collagen, the most abundant protein in the body, which causes problems such as arthritis, skin aging, autoimmunity, and fibrosis. When damaged, collagen loses its normal structure and binding sites, reducing the body’s ability to regenerate and respond correctly to problems. 3Helix’s solution, called bioACTIVE CHP, is a technology that binds to damaged collagen, providing signals and binding sites that fold back into their native environment, allowing cells to respond appropriately to their environment. Tests have shown that CHP can achieve responses several times higher than today’s best treatments.
“We are very excited about our bioACTIVE CHP technology, and the results we are seeing exceed even what we originally expected,” said Toby Barrack, vice president of 3Helix. ”. A set of collagen-based cellular signals and binding sites can be used to target and treat the cellular microenvironment. If cells were cars, most treatments would focus on hitting the gas or hitting the brakes. For the first time, you can change the traffic lights on your car. This approach is uniquely superior for inflammatory and fibrotic conditions, as well as other age-related changes. ”
Rebel Medicine developed Alevatrix as an injectable, long-acting, non-opioid anesthetic for postoperative pain. Currently, opioids are commonly used for this purpose, but they have a number of problems, including the risk of addiction and side effects such as respiratory depression, cognitive impairment, and nausea. Alevatrix provides safe and effective pain relief through a cost-effective, easy-to-use prefilled syringe that remains effective for up to four days post-surgery, eliminating the need for opioids and their associated negative effects. In preclinical studies, Alevatrix demonstrated strong analgesic effects in her two pig models. Clinical trials are expected to begin in the second half of 2024.
“Allevatrix provides clinicians with a safe, effective and affordable alternative to postoperative opioids. It can be used for almost any surgery, prevents new opioid addiction and improves patient outcomes. and is a powerful tool to reduce healthcare costs,” said Brett Davis, co-founder and CEO of Rebel Medicine.
Inherent Biosciences aims to accurately diagnose men suffering from infertility and hopes to improve the current standard of care. According to a report by the World Health Organization, one in six people around the world has difficulty conceiving, and although men account for half of the causes of infertility, women still bear the burden of testing. Too many. Inherent Biosciences’ Sperm Quality Test (SpermQT) analyzes the internal genetics of sperm, specifically sperm DNA methylation, to diagnose infertility more accurately than standard tests that simply count sperm and general movement patterns. Masu. This innovation aims to better understand male fertility and provide personalized and effective treatments to those facing fertility issues.
Andy Olsen, co-founder and CEO of Inherent Biosciences, said: “Many cases of male infertility go undiagnosed, and if men are not diagnosed, women are ineffective. He will receive treatment.” “With SpermQT, we aim to bring greater equity to the fertility journey, and this investment will help us complete our pivotal clinical trials to gain insurance coverage and inclusion in clinical guidelines. It’s helpful.”
Check out TechBuzz News’ December 2022 profile article about Inherent Biosciences and August 2023 article about the company’s $1.9 million NIH award.
“We are proud to support 3Helix, Rebel Medicine, Inherent Biosciences and their innovations,” added Utah Innovation Fund Director Tom Go. “We believe we have an opportunity to make a significant and positive impact on our community.” , onwards. “
In December 2023, the Utah Innovation Fund made its first investment of $250,000 in Eden Technologies, a St. George-based water desalination startup founded out of Utah Tech’s Atwood Innovation Plaza. announced.
[ad_2]
Source link
